bioRxivBioengineeringPreprint
A single dose SARS-CoV-2 simulating particle vaccine induces potent neutralizing activities
Y. Cai, D. Yin, S. Ling, X. Tian, Y. Li, Z. Xu, H. Jiang, X. ZhangiD, X. Wang, Y. Shi, Y. Zhang, L. Da, S.-c. Tao, Q. Wang, J. Xu, T. Ying, J. Hong
Abstract
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for which a vaccine is urgently needed to control its spreading. To facilitate the representation of a native-like immunogen without being infectious, here, we reported a SARS-CoV-2 vaccine candidate (designated ShaCoVacc) by incorporating spike-encoding mRNA inside and decorating spike protein on the surface of the virus simulating particles (VSPs) derived from lentiviral particles. We characterized the mRNA copy number, glycosylation status, transduction efficiency, and innate immune property of the new vaccine platform. Importantly, we showed the ShaCoVacc induced strong spike-specific humoral immune responses and potent neutralizing activities by a single injection. Additionally, we disclosed the epitopes of spike-specific antibodies using peptide microarray and revealed epitopes susceptible to specific neutralizing antibodies. These results support further development of ShaCoVacc as a candidate vaccine for COVID-19 and VSP may serve as a new vaccine platform for emerging infectious diseases.
- organism: human
- assay: protein sequence
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents
- mRNA-based vaccine candidate COReNAPCIN(R) induces robust humoral and cellular immunity in mice and non-human primates
R. Alimohammadi, M. Porgoo, … M. Azizi·bioRxiv·Mar 5, 2022
- Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination
A. Tscherne, J. H. Schwarz, … A. Volz·bioRxiv·Jan 9, 2021
- Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine induces equivalent preclinical antibody titers and viral neutralization to recovered COVID-19 patients
P. F. McKay, K. Hu, … R. J. Shattock·bioRxiv·Apr 22, 2020
- An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits potent immunity after a single dose.
A.-C. Fluckiger, B. Ontsouka, … C. Soare·bioRxiv·Apr 28, 2021
- Single immunization with recombinant ACAM2000 vaccinia viruses expressing the spike and the nucleocapsid proteins protect hamsters against SARS-CoV-2 caused clinical disease
J. Cao, Y. Deschambault, … D. Kobasa·bioRxiv·Dec 2, 2021